Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · SCHEDULE 13D/A

Valion Bio, Inc.

SEC Filing

Filed Aug 27, 2026Accepted Aug 27, 2026, 8:33 PM EDTCIK 1787740Accession 0001753926-26-001647
Share

Company context

We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act. An emerging growth company may take advantage of specified reduced reporting requirements that are otherwise generally applicable to public companies. As a result:

Current securities

Recent company filings

  1. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureSep 23, 2026
  2. SCHEDULE 13G/A filingSep 4, 2026
  3. SCHEDULE 13D/A filingSep 3, 2026
  4. SCHEDULE 13D/A filingSep 2, 2026
  5. Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureSep 1, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗